Posted on 18/01/08
QLT puts U.S. operations on the block
Struggling Vancouver pharmaceutical company QLT Inc. has begun its corporate overhaul by putting its U.S. operations on the market.The company said it will try to sell QLT USA Inc. as a whole or divest that unit's key products, which include the drug Eligard for prostate cancer and an acne treatment called Aczone.
The full text of this article has 539 words.
To continue reading this article, you will need to purchase this article.
Already have a member account? Login now
Pay-Per-View Offers To read the complete article, select one of the following options
Purchasing from globeandmail.com is quick and secure.
